8-K: OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights

OmniAb announced its third quarter 2024 financial results, showing a decrease in revenue compared to the same period last year, but highlighted progress in its partner programs and technology platform.

Summary

• OmniAb reported a revenue of $4.2 million for the third quarter of 2024, down from $5.5 million in the same period of 2023, primarily due to timing of milestones and lower ion channel service revenue.
• Research and development expenses decreased slightly to $13.3 million in Q3 2024 from $13.9 million in Q3 2023, mainly due to lower share-based compensation expenses.
• General and administrative expenses also decreased to $7.1 million in Q3 2024 from $8.5 million in Q3 2023, primarily due to lower legal and share-based compensation expenses.
• The net loss for the third quarter of 2024 was $16.4 million, or $0.16 per share, compared to a net loss of $15.7 million, or $0.16 per share, for the same period in 2023.
• Year-to-date revenue for the nine months ended September 30, 2024, was $15.6 million, compared to $29.3 million for the same period in 2023, due to lower milestone revenue.
• The company's net loss for the nine months ended September 30, 2024, was $49.0 million, or $0.48 per share, compared to a net loss of $36.6 million, or $0.37 per share, for the same period in 2023.
• As of September 30, 2024, OmniAb had $59.4 million in cash, cash equivalents, and short-term investments.
• OmniAb sold 2.0 million shares of common stock through its ATM program in Q3 2024, generating net proceeds of $8.5 million, and an additional 0.7 million shares after the quarter end for $2.9 million.
• The company expects total operating expenses in 2024 to be slightly less than in 2023 and anticipates ending 2024 with a cash balance between $50 million and $60 million.
• OmniAb expects cash use in 2025 to be lower than in 2024, excluding recent ATM program proceeds.

Sentiment

Score: 5

Explanation: The document presents mixed results. While there are positive developments in partner programs and technology expansion, the financial results show a significant decrease in revenue and an increase in net loss. The company is actively managing its cash position through ATM offerings, which is a necessary but not ideal situation. The sentiment is neutral to slightly negative due to the financial performance.

Positives

• OmniAb entered into three new platform license agreements in the third quarter of 2024, expanding its partnerships.
• The company expanded its ion channel screening relationship with Syngenta, indicating growth in this area.
• OmniAb has 86 active partners and 352 active programs, demonstrating a strong and diverse portfolio.
• Several partner programs are showing positive clinical results, including Immunovant's IMVT-1402 and batoclimab, Genmab's acasunlimab, Teva's TEV-53408, CStone's sugemalimab, and BioCity's BC3195.
• The company expects cash use in 2025 to be lower than in 2024, excluding recent ATM program proceeds, suggesting improved financial management.
• OmniAb expects total operating expenses in 2024 to be slightly less than in 2023, indicating cost control.

Negatives

• OmniAb's third quarter revenue decreased to $4.2 million from $5.5 million in the same period last year.
• Year-to-date revenue decreased significantly to $15.6 million from $29.3 million in the same period of 2023.
• The company's net loss for the nine months ended September 30, 2024, increased to $49.0 million from $36.6 million in the same period of 2023.
• The decrease in revenue was primarily due to the timing of milestones and lower ion channel service revenue.
• Amortization of intangible assets increased for the nine months ended September 30, 2024, primarily due to a $1.2 million impairment related to assets associated with two legacy unpartnered Ab Initio programs.

Risks

• OmniAb's future success depends on the acceptance of its technology platform by new and existing partners.
• The company's success is also dependent on the eventual development, approval, and commercialization of products developed by its partners, which are outside of OmniAb's direct control.
• Biopharmaceutical development is inherently uncertain, and there are risks associated with changes in technology.
• The company faces competition in the life sciences and biotechnology platform market.
• OmniAb must maintain, protect, and defend its intellectual property rights.
• The company relies on third parties for its business, and their performance could impact OmniAb's operations.
• Regulatory developments in the United States and foreign countries could pose risks.
• Unstable market and economic conditions may have adverse consequences on OmniAb's business, financial condition, and stock price.
• The company may use its capital resources sooner than expected.

Future Outlook

OmniAb expects total operating expenses in 2024 to be slightly less than in 2023 and anticipates ending 2024 with a cash balance between $50 million and $60 million. The company also expects cash use in 2025 to be lower than in 2024, excluding recent ATM program proceeds.

Management Comments

• Matt Foehr, Chief Executive Officer of OmniAb, stated that the third quarter results reflect consistent growth across key metrics, driven by planned initiatives and the dedication of the team.
• Matt Foehr also mentioned that the business is well capitalized and has a highly scalable model with cutting-edge technologies that are driving significant opportunities.
• Matt Foehr emphasized the company's focus on delivering value to stakeholders and creating sustainable, profitable growth.

Industry Context

This announcement reflects the ongoing challenges and opportunities in the biotechnology sector, where companies like OmniAb are focused on developing innovative technologies and partnering with pharmaceutical companies to advance drug development. The results highlight the variability in revenue due to milestone payments and the importance of a diverse partnership portfolio. The clinical progress of partner programs is a key indicator of the potential future success of OmniAb's technology.

Comparison to Industry Standards

• The decrease in OmniAb's revenue compared to the previous year is not uncommon in the biotech industry, where revenue can fluctuate based on milestone achievements and licensing agreements. Companies like AbCellera and Ligand Pharmaceuticals also experience variability in their quarterly revenues.
• OmniAb's R&D expenses are consistent with other biotech companies focused on platform technology development. Companies like Twist Bioscience and Ginkgo Bioworks also invest heavily in R&D.
• The net loss reported by OmniAb is typical for a company in its growth phase, where significant investments are made in research and development. Many biotech companies, such as Amyris and Intellia Therapeutics, also report net losses as they work towards commercializing their technologies.
• The cash balance of $59.4 million is a critical metric, and OmniAb's guidance to end 2024 with $50-60 million is important for investors to assess the company's financial stability. This is comparable to other companies in the sector that are actively managing their cash runway.
• The number of active partners (86) and programs (352) is a positive indicator of OmniAb's market traction and the demand for its technology. This is a key differentiator compared to smaller biotech companies with fewer partnerships.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and increase in net loss, but encouraged by the progress in partner programs and technology expansion.
• Employees may be motivated by the company's commitment to innovation and growth, but also aware of the financial challenges.
• Partners may be encouraged by the progress of their programs and the expansion of OmniAb's technology platform.
• Customers may benefit from the development of new therapeutics enabled by OmniAb's technology.
• Suppliers and creditors may be monitoring the company's financial performance and cash position.

Next Steps

• OmniAb will continue to advance its technology platform and expand its partnership portfolio.
• The company will focus on delivering value to stakeholders and creating sustainable, profitable growth.
• OmniAb will monitor the progress of its partner programs and provide updates on clinical and regulatory events.
• The company will manage its cash position and operating expenses to ensure financial stability.
• Immunovant is on track to initiate potentially registrational trials with IMVT-1402 by March 31, 2025.
• Immunovant will disclose data from batoclimab trials in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy by March 31, 2025.
• Data from batoclimab trials in thyroid eye disease are expected in the second half of calendar year 2025.
• Genmab is expected to start a Phase 3 trial for acasunlimab before the end of 2024.

Key Dates

Keywords

OmniAb, biotechnology, antibody discovery, platform technology, financial results, partner programs, clinical development, revenue, net loss, cash balance, ATM program, licensing agreements, transgenic animals, therapeutic discovery, ion channels